360 related articles for article (PubMed ID: 18580607)
1. The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.
Nattermann J; Vogel M; Nischalke HD; Danta M; Ahlenstiel G; Michalk M; Sauerbruch T; Rockstroh JK; Spengler U;
AIDS; 2008 Jul; 22(11):1287-92. PubMed ID: 18580607
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophilic patients in the presence or absence of human immunodeficiency virus (HIV) co-infection.
Picchio GR; Nakatsuno M; Boggiano C; Sabbe R; Corti M; Daruich J; Pérez-Bianco R; Tezanos-Pinto M; Kokka R; Wilber J; Mosier D
J Med Virol; 1997 Jun; 52(2):219-25. PubMed ID: 9179772
[TBL] [Abstract][Full Text] [Related]
3. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
Nattermann J; Vogel M; Berg T; Danta M; Axel B; Mayr C; Bruno R; Tural C; Klausen G; Clotet B; Lutz T; Grünhage F; Rausch M; Nischalke HD; Schewe K; Bienek B; Haerter G; Sauerbruch T; Rockstroh JK; Spengler U;
Hepatology; 2007 Oct; 46(4):1016-25. PubMed ID: 17668881
[TBL] [Abstract][Full Text] [Related]
4. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection.
Berger A; von Depka Prondzinski M; Doerr HW; Rabenau H; Weber B
J Med Virol; 1996 Apr; 48(4):339-43. PubMed ID: 8699166
[TBL] [Abstract][Full Text] [Related]
6. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype.
Schwarze-Zander C; Blackard JT; Zheng H; Addo MM; Lin W; Robbins GK; Sherman KE; Zdunek D; Hess G; Chung RT;
J Infect Dis; 2006 Aug; 194(4):410-9. PubMed ID: 16845623
[TBL] [Abstract][Full Text] [Related]
7. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
Deming P; McNicholl IR
Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection.
Barrett S; Collins M; Kenny C; Ryan E; Keane CO; Crowe J
J Med Virol; 2003 Oct; 71(2):212-8. PubMed ID: 12938195
[TBL] [Abstract][Full Text] [Related]
9. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
[TBL] [Abstract][Full Text] [Related]
10. HCV genotype distribution among HIV co-infected individuals in Argentina: relationship with host and viral factors.
Quarleri JF; Bolcic FM; Bouzas MB; Laufer N; Gómez Carrillo M; Mammana L; Kaufman S; Pérez H; Cahn P; Salomon H
Acta Gastroenterol Latinoam; 2007 Jun; 37(2):76-83. PubMed ID: 17684937
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.
Huckans MS; Loftis JM; Blackwell AD; Linke A; Hauser P
Subst Abuse Treat Prev Policy; 2007 Jan; 2():4. PubMed ID: 17222348
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hepatitis C].
Escuret V; Zoulim F
Rev Prat; 2005 Mar; 55(6):633-45. PubMed ID: 15913115
[TBL] [Abstract][Full Text] [Related]
14. HIV and hepatitis C virus coinfection: bad bedfellows.
Schooley RT
Top HIV Med; 2005; 13(4):112-6. PubMed ID: 16304454
[TBL] [Abstract][Full Text] [Related]
15. The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection.
Nischalke HD; Vogel M; Mauss S; Baumgarten A; Lutz T; Danta M; Naumann U; Coenen M; Sauerbruch T; Rockstroh JK; Spengler U; Nattermann J
AIDS; 2010 Aug; 24(13):2001-7. PubMed ID: 20588168
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.
Morsica G; Bagaglio S; Ghezzi S; Lodrini C; Vicenzi E; Santagostino E; Gringeri A; Cusini M; Carminati G; Bianchi G; Galli L; Lazzarin A; Poli G
J Clin Virol; 2007 Jun; 39(2):82-6. PubMed ID: 17434339
[TBL] [Abstract][Full Text] [Related]
17. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.
Ben-Ari Z; Pappo O; Druzd T; Sulkes J; Klein T; Samra Z; Gadba R; Tambur AR; Tur-Kaspa R; Mor E
Cytokine; 2004 Jul; 27(1):7-14. PubMed ID: 15207246
[TBL] [Abstract][Full Text] [Related]
18. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus.
Valle Tovo C; Alves de Mattos A; Ribeiro de Souza A; Ferrari de Oliveira Rigo J; Lerias de Almeida PR; Galperim B; Riegel Santos B
Liver Int; 2007 Feb; 27(1):40-6. PubMed ID: 17241379
[TBL] [Abstract][Full Text] [Related]
19. GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease.
Berzsenyi MD; Bowden DS; Roberts SK; Revill PA
J Gastroenterol Hepatol; 2009 Aug; 24(8):1407-10. PubMed ID: 19702909
[TBL] [Abstract][Full Text] [Related]
20. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
